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Precis:  Genetic association of the IL2RA with Japanese type 1 diabetes is different according to the 
mode of disease onset. 
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Abstract 
Context/Objective:  The interleukin-2 receptor α (IL2RA), also known as CD25, is expressed on the 
regulatory T cells which play an important role in the control of immune responses and the 
maintenance of immune homeostasis.  Our objective was to determine whether variants in the IL2RA 
gene are associated with type 1 diabetes in the Japanese population.  
Design/Patients:  We genotyped the four single-nucleotide polymorphisms (SNPs) (rs706778,  
rs3118470, ss52580101 and rs11594656) of the IL2RA in 885 patients with type 1 diabetes and 606 
control subjects of Japanese origin.  The allele and genotype frequencies were examined in the 
patient groups stratified by their mode of onset in a case-control study. 
Results:  We found evidence of association with acute-onset, but not slow-onset and fulminant, type 
1 diabetes for two of the 4 SNPs genotyped (rs706778 and rs3118470).  The rs706778 A allele and 
the rs3118470 G allele were associated with an increased disease risk (Odds ratio [OR] for rs706778 
AA genotype 1.54, P = 4.2 x 10-4 and OR for rs3118470 GG genotype 1.50, P = 0.0019, respectively).  
Furthermore, the A-G haplotype was associated with increased type 1 diabetes risk in acute-onset form 
(OR 1.30, P = 0.002). 
Conclusions:  The present data confirmed the type 1 diabetes association with IL2RA and provide 
evidence that the different contributions of the IL2RA in the susceptibility to acute-onset and other 




Type 1 diabetes is known as a multigenic 
organ-specific autoimmune disease 
characterized by T-cell–dependent destruction 
of the insulin-producing pancreatic β-cells, 
resulting in absolute dependence on insulin for 
survival and maintenance of health (1).  
Clinical features of Japanese type 1 diabetes 
are heterogeneous and there are at least three 
subtypes of type 1 diabetes in Japan, 
acute-onset ‘classical’, slow-onset, and 
fulminant type 1 diabetes (2).  However, the 
underlying pathogenesis of β-cell destruction, 
including the genetic or environmental factors 
for each subtype of type 1 diabetes is largely 
unknown. 
Recent first-stage results of genome-wide 
association (GWA) studies identified several 
loci other than the HLA on chromosome 6p21, 
the insulin gene (INS-VNTR) on 11p15, the 
CTLA4 locus on 2q33, and the PTPN22 on 
1p13 include IL2RA locus on 10p15, IFIH1 on 
2q24 and, most recently, CLEC16A 
(KIAA0350) on 16p13, and PTPN2 on 18p11 
(3-5).  The IL2RA encodes the α-chain of the 
IL-2 receptor (IL-2R) complex (also known as 
CD25) which is central to immune regulation 
as an important modulator of self-tolerance 
and immunity (6) and the IL2RA association 
with type 1 diabetes was originally identified 
by Vella and coworkers (7).  IL2RA 
expression on CD4+ CD25+ regulatory T cells 
is essential for their function in suppressing T 
cell immune responses to autoantigens, 
alloantigens, tumor antigens, and 
pathogen-derived antigens.  As direct 
evidence of the importance of CD4+ CD25+ 
regulatory T cells in human type 1 diabetes (8, 
9), depletion of regulatory T cells by 
anti-CD25 antibody hastened development of 
diabetes in non-obese diabetic mice, an animal 
model of spontaneous type 1 diabetes (10).  
Furthermore, it has been evidenced that the 
type 1 diabetes-associated polymorphisms in 
the IL2RA region regulate the circulating 
concentration of soluble form of IL2RA (11).  
These findings implicate that the genetic 
associations of IL2RA polymorphisms to the 
rate of β-cell destruction in type 1 diabetes.  
In this study, we demonstrated the differences 
in the contribution of IL2RA polymorphisms to 
susceptibility to acute-onset, slow-onset, and 
fulminant type 1 diabetes in the Japanese 
population. 
 
Subjects and Methods 
Subjects 
We examined 885 patients with type 1 
diabetes (56% female) and 606 healthy control 
subjects of Japanese origin.  Patients with 
type 1 diabetes include 627 patients with 
acute-onset (57% female), 222 with slow-onset 
(56% female) and 25 with fulminant type 1 
diabetes (28% female).  The remaining 11 
patients were unclassified type 1 diabetes.  
The criterion for the recruitment of acute-onset 
type 1 diabetes were 1) presence of diabetic 
ketosis at onset, 2) the duration of 
hyperglycemic symptoms before starting 
insulin therapy was < 3 months, 3) positive for 
at least one of the anti-islet autoantibodies.  
Diagnosis of slow-onset type 1 diabetes were 
done by the following criteria: 1) originally 
diagnosed as type 2 diabetic and no sign of 
ketosis at diabetes onset; 2) proven anti-islet 
autoantibody positivity; and 3) insulin 
treatment started ≥12 months after the 
diagnosis.  Diagnostic criteria for fulminant 
type 1 diabetes were described elsewhere (2).  
The median age-at-onset and serum C-peptide 
concentration of acute-onset, slow-onset and 
fulminant type 1 diabetes was 21.0, 40.0, and 
44.0 years and 0.14, 0.45, and 0.005 ng/ml, 
respectively.  The associations of clinical and 
genetic parameters such as age-at-onset, 
gender, co-occurrence of autoimmune thyroid 
disease (AITD), glutamic acid decarboxylase 
65 (GAD65) autoantibody titer, CTLA4 and 
class II HLA with IL2RA risk haplotype were 
also examined.  AITD was defined as Graves' 
disease, Hashimoto's thyroiditis which were 
diagnosed based on the finding of palpable 
goiter or the presence of chronic thyroiditis 
with ultrasonography examination in the 
absence of goiter, abnormal levels of thyroid 
hormones, and positivity for autoantibodies to 
4 
thyroid peroxidase, thyroglobulin and/or 
thyrotropin receptor.  The healthy control 
subjects had normal glucose tolerance and no 
family history of type 1 diabetes or other 
autoimmune diseases.  This study was 
approved by the appropriate ethical 
committees and informed consent was 
obtained from all subjects. 
 
Genotyping 
Two SNPs in intron 1 of the IL2RA, 
rs706778 A>G and rs3118470 A>G, and two 
SNPs in the 5’ regions of the IL2RA and 
RBM17, ss52580101 (rs41295061) C>A and 
rs11594656 T>A, were genotyped.  
Genotyping of the rs706778 A>G was 
performed by PCR-restriction fragment length 
polymorphism (RFLP) method (1.5 mM 
MgCl2, Tanneal 58°C) with forward primer 
(rs706778F2); 
5’-TCCCCTTTCTCTTCTCTCAG-3’ and 
reverse primer (rs706778R3); 
5’-GAGCCCTGAGGGACTAGTAAATTTCC
ACCA-3’ followed by digestion with Bsr I 
(New England Biolabs, Ipswich, MA).  The 
rs3118470 A>G was genotyped by PCR-RFLP 




reverse primer (rs3118470R3); 
5’-AGCCCCAAGGGATCAGTAAATTTCCA
CCA-3’ followed by digestion with Bsr I.  
The ss52580101 C>A was genotyped by 
PCR-RFLP (2.0 mM MgCl2, Tanneal 62°C) with
 
forward primer (rs41295061F); 
5’-CACCCTCATCCATAAAGACC-3’ and 
reverse primer (rs41295061R); 
5’-ATTCATCCCACACCCACCAG-3’ 
followed by digestion with Mwo I.  Finally, 
the rs11594656 T>A was genotyped by 
PCR-RFLP (2.0 mM MgCl2, Tanneal 58°C) with
 
forward primer (rs11594656F); 
5’-CTCCCCAGTCATTCACCAAA-3’ and 
reverse primer (rs11594656R); 
5’-TCTTTTGGCTTTTCTCACTATGATGCC
GTC-3’ followed by digestion with BsmA I.  
The digested products were resolved on a 3.5% 
agarose gel and stained with ethidium bromide.  
The number of cases and controls we were 
able to genotype were 877 and 602 for 
rs706778, 872 and 592 for rs3118470, 881 and 
606 for ss52580101, and 882 and 606 for 
rs11594656, respectively.  No deviations 
from Hardy-Weinberg equilibrium were 
observed for all genotypes in control subjects.  
The HLA-DR and +6230G>A (CT60, 
rs3087243) in the CTLA4 were also genotyped 
as reported previously (12).  The data on 
HLA-DR and CTLA4 +6230G>A 
polymorphism were available in 587 and 798 
patients with type 1 diabetes, respectively. 
 
Anti-islet autoantibody assays 
Autoantibodies to glutamic acid 
decarboxylase 65 (GAD65), insulinoma 
associated antigen-2 (IA-2), insulin, and zinc 
transporter-8 (ZnT8) were measured by 
radioimmunoassay and islet cell antibodies 
(ICA) were determined by immunoenzymatic 
staining of human pancreas sections, as 
described previously (13, 14).  Subjects 
positive for at least one of autoantibodies to 
GAD65, IA-2, ZnT8, insulin and/or ICA were 




A 2 test was used for statistical analysis 
unless otherwise indicated. Odds ratio and its 
95% confidence interval (95% CI) was also 
calculated.  Haplotype frequencies were 
estimated based on the HPlus v2.5 software 
program (http://qge.fhcrc.org/hplus/) (15).  
Linkage disequilibrium, evaluated by D’ 
coefficients, was calculated to evaluate linkage 
disequilibrium by Haploview v4.0 software 
(http://www.broad.mit.edu/mpg/haploview).  
Deviations from Hardy-Weinberg equilibrium 
were tested by comparison of observed and 
expected genotype frequencies.  Patient-only 
logistic regression analysis was performed to 
test for the association of the IL2RA risk 
haplotype with age at onset, gender, 
co-occurrence of AITD, log-transformed 
GAD65 autoantibody titer, class II HLA and 
CTLA-4 CT60 genotype as variables.  
StatView Ver.5.0 (SAS Institute, Cary, NC) 
were used for these tests.  A P value less than 




IL2RA variants and type 1 diabetes 
First, we compared IL2RA genotype and 
allele frequencies between the overall type 1 
diabetes and control subjects.  Among the 
four SNPs genotyped in this study, two SNPs 
(rs706778 and rs3118470) had statistically 
significant type 1 diabetes association.  As 
shown in Table 1, the AA genotype at 
rs706778 SNP and the GG genotype at 
rs3118470 SNP were significantly associated 
with type 1 diabetes (OR 1.37, 95%CI: 
1.09-1.71, P = 0.0062 for rs706778 and OR 
1.28, 95%CI: 1.00-1.63, P = 0.048 for 
rs3118470). 
 
Association of IL2RA variants with mode of 
diabetes onset and class II HLA 
Then we divided these patients into three 
groups (acute-onset, slow-onset, and 
fulminant) according to the mode of diabetes 
onset and examined the genetic contribution of 
the two significant IL2RA SNPs in each group 
(Table 2).  We found a significant genetic 
association between the IL2RA and acute-onset 
type 1 diabetes (OR 1.54, 95%CI: 1.21-1.96, P 
= 4.2 x 10-4 for rs706778 and OR 1.50, 95%CI: 
1.16-1.94, P = 0.0019 for rs3118470), whereas 
no significant difference was observed 
between slow-onset type 1 diabetes, fulminant 
type 1 diabetes and control subjects (Table 2).  
Furthermore, the stratification of acute-onset 
patients by the presence or absence of high 
diabetes risk class II HLA (DR4/4, 4/X, 9/9, 
but not DQB1*0601/*0602) showed that the 
disease association of IL2RA polymorphisms 
was observed only in patients carrying high 
diabetes risk HLA (OR 1.52, 95%CI: 1.13-2.04, 
P = 5.5 x 10-4 for rs706778 and OR 1.48, 
95%CI: 1.08-2.02, P = 0.015 for rs3118470).  
Therefore, the association of IL2RA with 
Japanese type 1 diabetes originates in the 
association with acute-onset patients, 
especially with patients carrying high risk class 
II HLA.  However, neither the ss52580101 
nor rs11594656 were associated with mode of 
diabetes onset and class II HLA (data not 
shown). 
 
IL2RA haplotype analysis 
Two significant IL2RA SNPs are in high 
linkage disequilibrium (D’ = 0.953, r2 = 0.69) 
and rs706778A;rs3118470G haplotype 
(frequency 52.3%) was associated with 
increased risk in acute-onset type 1 diabetes 
(OR 1.30, 95%CI 1.10-1.53, P = 0.002) (Table 
3). 
 
Association with clinical and genetic 
parameters of type 1 diabetes 
We evaluated the relationship of the 
disease associated IL2RA haplotype with 
clinical and genetic parameters in acute-onset 
patients by logistic regression analysis (Table 
4).  There were no associations of IL2RA risk 
haplotype with age-at-onset, gender, GAD65 
autoantibody titer or presence of established 
genetic risk factors for Japanese type 1 
diabetes such as the carriage of the CTLA4 
CT60GG genotype and high risk HLA-DR 
genotype.  However, the IL2RA risk 
haplotype was associated with the 
co-occurrence of thyroid autoimmunity (OR 
1.66, 95%CI 1.00-2.75, P = 0.048).  In 
patients with slow-onset type 1 diabetes, any 
clinical and genetic parameters were not 




We demonstrated 1) the type 1 diabetes 
association of the SNPs in the IL2RA and 2) 
the differences in the contribution of IL2RA to 
susceptibility of type 1 diabetes depending on 
the mode of diabetes onset in the Japanese 
population.  Furthermore, it was suggested 
that the class II HLA have influence on the 
association of type 1 diabetes with the IL2RA. 
The association of IL2RA variants with 
acute-onset, but not with slow-onset and 
fulminant, type 1 diabetes suggests that IL2RA 
might relate to the rate of autoimmune β-cell 
destruction.  The different contributions of 
type 1 diabetes susceptibility gene in the mode 
of diabetes onset have been also documented 
in class II HLA, CTLA4, PTPN22, and NeuroD 
in the Japanese population (16-19).  
Therefore, the underlying immune process 
primed β-cell injury might be distinct between 
subtypes of type 1 diabetes (acute, slow, and 
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fulminant). 
The IL2R-signaling complex is 
composed of three distinct subunits, the 
α-chain (CD25), β-chain (CD122), and γ-chain 
(CD132) each of which have unique roles in 
facilitating IL2-dependent signal transduction 
(6).  Among these IL2Rα acts to confer 
high-affinity binding of IL2 to the IL2R 
complex highly expressed by activated T-cells 
and CD4+ CD25+ regulatory T cells.  The 
IL2RA gene has also been associated with 
Graves’ disease (20), rheumatoid arthritis (4) 
and multiple sclerosis (21) which imply that 
this locus may have a general effect on 
predisposition to autoimmunity.  Since the 
involvement of IL2R complex on the 
regulation of immune function is not limited to 
the specific-organs (6), the current observation 
showing the much stronger association 
between IL2RA polymorphisms and type 1 
diabetes with AITD is consistent with this 
hypothesis. 
Two SNPs associated with Japanese type 
1 diabetes in this study (rs706778 and 
rs3118470) are located in intron 1 and have 
been reported the type 1 diabetes association in 
two independent studies in subjects of British 
and Canadian descent (11, 22).  Furthermore, 
recent WGA study reported that other SNPs 
close to these two SNPs (< 300bp distance), 
rs12722489 and rs2104286, had a significant 
association with multiple sclerosis (21).  
Taken together, these results implicate that 
causal variants for multiple autoimmune 
diseases localize in the IL2RA intron 1.  Of 
note, the two most associated markers with 
European patients (11), ss52580101 
(rs41295061) and rs11594656, were less 
polymorphic in Japanese population compared 
to white populations and were not associated 
with Japanese type 1 diabetes, suggesting that 
there is an allelic heterogeneity between 
Japanese and white populations. 
To date, at least six positive regulatory 
regions have been identified in the regulation 
of IL2RA expression in the promoter region 
and intron 1 (6).  Although it is unknown how 
rs706778 and rs3118470 SNPs in intron 1 act 
to influence the expression of IL2RA, 
searching the TFSEARCH transcription factor 
binding site data base with the DNA sequence 
surrounding the SNPs sites identified the 
binding site for the Cut-like repressor protein 
(CR3HD) on the antisense strand of both SNPs.  
The polymorphic nucleotide in rs706778 A>G 
and rs3118470 A>G is located at the critical 
region of the core motif of the CR3HD binding 
consensus sequence (cATTGATgga; core motif 
is shown in uppercase, the position at 
polymorphic site is in bold) (23).  
Furthermore, it is reported that single 
nucleotide substitution in the Cut-like protein 
binding site of the TGF-β type II receptor gene 
(TβR-II) promoter increase the CR3HD 
binding affinity which induce the reduction of 
TβR-II transcription (24).  Thus, it is possible 
that these SNPs may be involved in regulating 
the IL2RA transcription or altering the splicing 
of the IL2RA transcript, which could affect the 
regulatory T cell functions.  Further studies of 
expression of IL2RA transcripts in different 
blood cell subsets, together with the 
transfection experiment with CR3HD 
transcription factor are required to characterize 
the functional role of these SNPs.  In 
conclusion, the present study indicated that 
IL2RA is associated with Japanese type 1 
diabetes and its contribution to susceptibility to 
type 1 diabetes is different according to the 
mode of diabetes onset. 
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n AA Aa aa 
OR * 
(95%CI) 





Controls  602 170 (28.2) 309 (51.3) 123 (20.4) 649 (53.9) 








Controls  592 159 (26.9) 298 (50.3) 135 (22.8) 616 (52.0) 
Type 1 diabetes 872 206 (23.6) 427 (49.0) 239 (27.4)
1.28 
(1.00-1.63) 





Controls  606 605 (99.8) 1 (0.2) 0 (0.0) 1211 (99.9)
Type 1 diabetes 881 881 (100) 0 (0.0) 0 (0.0) NA 
 
1762 (100) NA 
 
rs11594656 T>A 
Controls  606 570 (94.1) 35 (5.8) 1 (0.2) 1175 (96.9)







Data are n (%) unless otherwise indicated.  A, major allele; a, minor allele.  * AA vs. Aa+aa for rs706778 and rs11595656, aa vs. AA+Aa for rs3118470 
NS, not significant.  NA, not applicable 
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Table 2  IL2RA polymorphisms in patients with type 1 diabetes classified by mode of diabetes onset 
  




n 623 219 24 602 
Genotype frequencies 
AA 235 (37.7) 63 (28.8) 7 (29.2) 170 (28.2) 
AG 281 (45.1) 122 (55.7) 12 (50.0) 309 (51.3) 
GG 107 (17.2) 34 (15.5) 5 (20.8) 123 (20.4) 







(0.43-2.57)   
P value * 0.00042 NS NS 
Allele frequencies 
A 751 (60.3) 248 (56.6) 26 (54.2) 649 (53.9) 








(0.57-1.80)   
P value 0.0014 NS NS 
rs3118470 A>G 
n 622 221 25 592 
Genotype frequencies 
AA 145 (23.3) 51 (23.1) 8 (32.0) 159 (26.9) 
AG 286 (46.0) 128 (57.9) 12 (48.0) 298 (50.3) 
GG 191 (30.7) 42 (19.0) 5 (20.0) 135 (22.8) 







(0.31-2.30)   
P value * 0.0019 NS NS 
Allele frequencies 
A 576 (46.3) 230 (52.0) 28 (56.0) 616 (52.0) 








(0.66-2.08)   
P value 0.0048 NS NS 
Data are n (%) unless otherwise indicated.  Genotype and allele frequencies were compared between type 1 
diabetes and control subjects.  * AA vs. AG+GG for rs706778, GG vs. AG+AA for rs3118470.  NS, not 
significant 
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Table 4  Logistic regression analysis for the association of clinical and genetic parameters with IL2RA 
risk haplotype among acute-onset patients with type 1 diabetes 
 rs706778: rs3118470 
A:G haploype (+) vs A:G haploype (-) 
Variable OR 95% CI P value 
Age at onset (year)  0.99 0.98-1.01 NS 
Male  0.87 0.60-1.29 NS 
With AITD  1.66 1.00-2.75 0.048 
GAD65 autoantibody titer  1.14 0.74-1.75 NS 
CTLA4 CT60GG present  1.01 0.69-1.50 NS 
High-risk HLA-DR present  1.31 0.78-2.20 NS 
AITD, autoimmune thyroid disease. CT60, CTLA4 +6230G>A. High-risk HLA-DR, DR4/4, 4/X, 9/9, but not 
DQB1*0601/*0602. NS, Not significant 
